论文部分内容阅读
目的:对比硼替佐米联合地塞米松(BD)方案和沙利度胺联合地塞米松(TD)方案对老年多发性骨髓瘤患者的疗效及不良反应。方法:回顾性分析24例老年多发性骨髓瘤病例,随机分为BD组和TD组,统计分析2组的缓解率及生存时间。结果:4个疗程后,BD组完全缓解(CR)4例,部分缓解(PR)6例,TD组完全缓解2例,部分缓解4例。BD组2年存活9例,4年存活5例,TD组2年存活6例,4年存活3例。BD组缓解率,生存期优于TD组。结论:BD方案较TD方案更适于老年多发性骨髓瘤患者的化疗。
Objective: To compare the efficacy and side effects of bortezomib with dexamethasone (BD) and thalidomide plus dexamethasone (TD) in elderly patients with multiple myeloma. Methods: A retrospective analysis of 24 cases of elderly patients with multiple myeloma, were randomly divided into BD group and TD group, statistical analysis of two groups of remission rate and survival time. Results: Four courses of complete remission (CR) occurred in 4 cases, partial remission (PR) in 6 cases, complete remission in 2 cases and partial remission in 4 cases in TD group. In the BD group, 9 patients survived 2 years, 5 patients survived 4 years, 6 patients survived 2 years and 3 patients survived 4 years. BD group remission rate, survival is better than the TD group. Conclusion: BD is more suitable than TD for chemotherapy in elderly patients with multiple myeloma.